Condition (MeSH)
Pulmonary Emphysema
ClinicalTrials.gov lists 64 trials for Pulmonary Emphysema or a narrower condition beneath it. Aeris Therapeutics has the most among industry and government lead sponsors, with 13.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
64 of the 64 trials are tagged with Pulmonary Emphysema itself; the rest are tagged with a narrower condition beneath it.
When did Pulmonary Emphysema trials start? (20)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 2/3
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 6
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 2 |
| 2025 | 4 |
| 2024 | 2 |
| 2021 | 1 |
| 2020 | 2 |
| 2019 | 2 |
| 2016 | 3 |
| 2015 | 4 |
| 2014 | 5 |
| 2013 | 5 |
Showing 10 of 20 earlier years.
No forecast is made for this condition: it averages 1.6 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 4 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Pulmonary Emphysema trials in? (8)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 3 |
| Phase 1/2 | 5 |
| Phase 2 | 8 |
| Phase 2/3 | 4 |
| Phase 3 | 8 |
| Phase 4 | 4 |
| Not applicable | 18 |
| Observational | 14 |
How many Pulmonary Emphysema trials are recruiting? (6)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Recruiting | 6 |
| Enrolling by invitation | 1 |
| Completed | 39 |
| Terminated | 10 |
| Withdrawn | 1 |
Showing 5 of 6 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Pulmonary Emphysema trials? (7)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Aeris Therapeutics | 13 |
| Grifols Therapeutics LLC | 6 |
| Pulmonx Corporation | 3 |
| Olympus Corporation of the Americas | 2 |
| AstraZeneca | 1 |
Showing 5 of 7 sponsors.
Interventions as named in the registry (15)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Alpha-1 MP | 3 |
| Alpha1-antitrypsin | 2 |
| BLVR Hydrogel | 2 |
| Medical Management | 2 |
| Alpha-1 15% | 2 |
Showing 5 of 15 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Pulmonary Emphysema trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Cardiac Event | 4 | 1 |
| Chronic obstructive pulmonary disease | 2 | 1 |
| Acute promyelocytic leukaemia | 1 | 1 |
| Cervical spinal stenosis | 1 | 1 |
| Chronic respiratory failure | 1 | 1 |
Showing 5 of 10 adverse events.
Which publications cover Pulmonary Emphysema? (477)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Zone of z-scores uncertainty in pulmonary function interpretation: A proof-of-concept study from CO and NO lung diffusing capacities. | Respiratory medicine | 2026 | Yes |
| Airway Scaffolds for Emphysema-related Hyperinflation: Six-Month Results from the BREATHE Trial. | American journal of respiratory and critical care medicine | 2025 | Yes |
| Clinical and Prognostic Differences in Mild to Moderate COPD With and Without Emphysema. | Chest | 2025 | Yes |
| Dupilumab reduces exacerbations and improves lung function in patients with chronic obstructive pulmonary disease and emphysema: Phase 3 randomized trial (BOREAS). | Respiratory medicine | 2025 | Yes |
| Mapping Bullous Emphysema With Lung Ultrasound: A Prospective Multicentre Study. | Respirology (Carlton, Vic.) | 2025 | Yes |
Showing 5 of 477 publications.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence, rare-disease identity, and sub-conditions in mesh.